Want to see TSE:PHRM full AI Analyst Report?
PHRM Stock Chart & Stats
C$0.10
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.10
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.05 - C$0.77
Previous CloseN/A
Volume18.00K
Average Volume (3M)158.34K
Market Cap
C$4.55M
Enterprise ValueC$4.21M
Total Cash (Recent Filing)C$861.47K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta-0.25
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding91,019,066
10 Day Avg. Volume117,358
30 Day Avg. Volume158,340
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)16.46
Price to Sales (P/S)0.00
P/FCF Ratio-13.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)C$83.60M
Bulls Say, Bears Say
Bulls Say
Low Leverage / No Reported DebtZero reported debt is a durable strength: it reduces fixed financial obligations and preserves flexibility to fund R&D or bridge development milestones without immediate interest burdens. This lowers bankruptcy risk and gives management optionality for capital structure choices over months.
Material Narrowing Of Net LossesSustained reduction in net losses signals meaningful operational discipline and cost control. For a pre-revenue biotech, narrowing losses lengthen runway per financing dollar and improve prospects of reaching clinical inflection points with less dilution, a structural improvement in execution.
Improving Cash Burn TrendAn improving cash-burn trajectory is a durable operational positive: lower negative operating cash flows reduce near-term financing needs and indicate better resource allocation. If sustained, this materially eases funding pressure while the drug development timeline progresses.
Bears Say
Pre-revenue StatusNo commercial revenue means the business remains fully dependent on successful clinical outcomes and external financing. This structurally elevates execution and regulatory risk: until products commercialize, profitability and self-sustaining cash generation are uncertain.
Shrinking Equity BaseRapid erosion of shareholders' equity materially weakens the balance-sheet cushion against setbacks. A thin equity base reduces financial flexibility and increases the probability of dilutive financing or constrained responses to adverse trial or regulatory outcomes over the coming months.
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow necessitate repeated external capital raises. In a specialty biotech, recurring financing risk is structural: it can cause dilution, timing dependence on markets, and constrain long-term planning unless commercial revenues emerge or financing terms materially improve.
PharmaTher Holdings Ltd News
PHRM FAQ
What was PharmaTher Holdings Ltd’s price range in the past 12 months?
PharmaTher Holdings Ltd lowest stock price was C$0.05 and its highest was C$0.77 in the past 12 months.
What is PharmaTher Holdings Ltd’s market cap?
PharmaTher Holdings Ltd’s market cap is C$4.55M.
When is PharmaTher Holdings Ltd’s upcoming earnings report date?
PharmaTher Holdings Ltd’s upcoming earnings report date is Sep 24, 2026 which is in 73 days.
How were PharmaTher Holdings Ltd’s earnings last quarter?
PharmaTher Holdings Ltd released its earnings results on Jan 30, 2026. The company reported -C$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.003.
Is PharmaTher Holdings Ltd overvalued?
According to Wall Street analysts PharmaTher Holdings Ltd’s price is currently Overvalued.
Does PharmaTher Holdings Ltd pay dividends?
PharmaTher Holdings Ltd does not currently pay dividends.
What is PharmaTher Holdings Ltd’s EPS estimate?
PharmaTher Holdings Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmaTher Holdings Ltd have?
PharmaTher Holdings Ltd has 91,019,066 shares outstanding.
What happened to PharmaTher Holdings Ltd’s price movement after its last earnings report?
PharmaTher Holdings Ltd reported an EPS of -C$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of PharmaTher Holdings Ltd?
Currently, no hedge funds are holding shares in TSE:PHRM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PharmaTher Holdings Ltd
PharmaTher Holdings Ltd. operates as a clinical-stage biotechnology firm, primarily focused on psychedelic compounds. It is dedicated to investigating, advancing, and bringing to market innovative applications, formulations, and administration techniques for psychedelics to treat a range of conditions including mental health disorders, neurological ailments, and chronic pain. A key asset in its development portfolio is an intravenous ketamine injection, currently undergoing Phase II and III clinical evaluations targeting indications such as Parkinson's disease, anesthesia/sedation, and amyotrophic lateral sclerosis (ALS). The company's pipeline further features a Ketamine Patch, which is progressing through Phase I and II clinical trials for the treatment of depression, various mental health conditions, complex regional pain syndrome (CRPS), and other pain-related disorders. Additionally, a Ketamine Pump is undergoing Phase II clinical assessment for use in mental health, pain management, and surgical/procedural settings. Beyond these, PharmaTher is actively developing PHARMAPATCH, an innovative microneedle patch designed for psychedelic drug delivery. The company has established strategic collaboration agreements with several partners, including LTS Lohmann Therapie-Systeme AG for developing a ketamine microneedle patch; Alcami Corporation for the advancement of ketamine injectables and infusions; BioRAE, Inc. for the development of ketamine pump technology; Revive Therapeutics Ltd. to develop a psilocybin microneedle patch; and Gesval S.A. for the development of patented continuous-flow process technology for synthesizing ketamine and its analogs. PharmaTher is also internally dedicated to creating its own proprietary wearable ketamine delivery system, intended for addressing mental health, neurological, and pain conditions. Established in 2019, the company maintains its headquarters in Toronto, Canada.
Technical Analysis
COSCIENS Biopharma
―
Kane Biotech
―
BetterLife Pharma
―
BioVaxys Technology
―
Marvel Biosciences Corp
―
Options Prices
Currently, No data available
---